At the news
? BULLISHIMPACT 7/10 8-K filed Aug 18, 2026 at 08:39 ET
BioMarin (BMRN) entered into a definitive Share Purchase Agreement to acquire Alesta Therapeutics for $275 million upfront in cash, with up to $215 million in additional milestone-based payments, for a total potential consideration of up to $490 million. Alesta's lead asset is ALE-1, an oral small-molecule in a Phase 1/2a trial for hypophosphatasia (HPP). The deal is expected to close in Q3 2026, funded from cash on hand.
- BioMarin to acquire Alesta Therapeutics for $275M upfront cash, subject to customary post-closing purchase price adjustment.
- Up to $215M in additional milestone payments tied to development and regulatory achievements for ALE-1.
- ALE-1 is an orally active small molecule in Phase 1/2a for hypophosphatasia (HPP), a rare genetic bone disease with over 9,000 diagnosed patients in the US.
- Alesta will spin out all non-ALE1 assets to a new entity (Anaheim SpinCo) prior to closing; no Alesta employees will join BioMarin.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access